Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) has been given a $14.00 target price by Canaccord Genuity in a research note issued on Friday. The brokerage currently has a “hold” rating on the specialty pharmaceutical company’s stock. Canaccord Genuity’s target price would suggest a potential downside of 7.47% from the stock’s current price.

Several other research analysts have also commented on VRX. Piper Jaffray Companies reiterated an “outperform” rating and set a $10.00 price target on shares of Valeant Pharmaceuticals International in a report on Friday, April 14th. Mizuho reiterated an “underperform” rating and set a $8.00 price target (down previously from $9.00) on shares of Valeant Pharmaceuticals International in a report on Monday, April 17th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $18.00 price target on shares of Valeant Pharmaceuticals International in a report on Wednesday, April 19th. Deutsche Bank AG reduced their price target on Valeant Pharmaceuticals International from $19.00 to $18.00 and set a “hold” rating on the stock in a report on Wednesday, April 19th. Finally, J P Morgan Chase & Co reduced their price target on Valeant Pharmaceuticals International from $15.00 to $10.00 and set a “neutral” rating on the stock in a report on Thursday, April 20th. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and an average target price of $16.96.

Valeant Pharmaceuticals International (NYSE:VRX) traded down 2.07% on Friday, reaching $15.13. 18,721,769 shares of the company’s stock were exchanged. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $32.74. The firm has a 50 day moving average price of $16.16 and a 200 day moving average price of $13.34. The firm’s market cap is $5.26 billion. Valeant Pharmaceuticals International also was the target of unusually large options trading on Thursday. Traders bought 16,974 put options on the stock. This represents an increase of approximately 100% compared to the typical daily volume of 8,473 put options.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, topping the consensus estimate of $0.87 by $1.93. Valeant Pharmaceuticals International had a positive return on equity of 58.02% and a negative net margin of 14.96%. The business had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.17 billion. During the same quarter in the previous year, the firm earned ($1.08) EPS. The company’s quarterly revenue was down 11.1% compared to the same quarter last year. On average, equities analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Canaccord Genuity Analysts Give Valeant Pharmaceuticals International, Inc. (VRX) a $14.00 Price Target” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/08/06/canaccord-genuity-analysts-give-valeant-pharmaceuticals-international-inc-vrx-a-14-00-price-target.html.

In other news, Director Schutter Richard U. De bought 20,000 shares of the company’s stock in a transaction on Thursday, May 11th. The stock was bought at an average cost of $13.90 per share, with a total value of $278,000.00. Following the transaction, the director now directly owns 70,572 shares in the company, valued at approximately $980,950.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 5.87% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Gruss & Co. Inc. purchased a new position in Valeant Pharmaceuticals International during the first quarter valued at $104,000. Financial Architects Inc increased its position in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares in the last quarter. Harbor Advisors LLC purchased a new position in Valeant Pharmaceuticals International during the first quarter valued at $110,000. WMS Partners LLC purchased a new position in Valeant Pharmaceuticals International during the first quarter valued at $116,000. Finally, Brave Asset Management Inc. purchased a new position in Valeant Pharmaceuticals International during the first quarter valued at $119,000. 50.53% of the stock is owned by institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.